Platelets are the “guardians” of the blood circulatory system. At sites of vessel injury, they
ensure hemostasis and promote immunity and vessel repair. However, their uncontrolled …

In platelets, the nitric oxide (NO)–induced cGMP response is indicative of a highly regulated
interplay of cGMP formation and cGMP degradation. Recently, we showed that within the NO …

It is generally accepted that nitric oxide (NO) donors, such as sodium nitroprusside (SNP), or
phosphodiesterase 5 (PDE5) inhibitors, including sildenafil, each impact human platelet …

Intracellular cyclic GMP (cGMP) inhibits platelet function. Platelet cGMP levels are controlled
by phosphodiesterase 5A (PDE5A)-mediated degradation. However, the exact role of …

It is now almost 30 years since the discovery that prostaglandin E 1 (PGE 1) inhibits platelet
responses to aggregating agents, together with finding that the effects of this compound are …

Platelets are specialized adhesive cells that play a key role in normal and pathological
hemostasis through their ability to rapidly adhere to subendothelial matrix proteins (platelet …

Platelets play a key role in hemostasis through their ability to rapidly adhere to activated or
injured endothelium, subendothelial matrix proteins, and other activated platelets. A strong …

Phosphodiesterase type 3 (PDE3) is an important regulator of cAMP-mediated responses
within the cardiovascular system. PDE3 exists as two subtypes: PDE3A and PDE3B, with …

Platelets are circulating sentinels of vascular integrity and are activated, inhibited, or
modulated by multiple hormones, vasoactive substances or drugs. Endothelium-or drug …

There are two primary modes of platelet inhibition: blockade of membrane receptors or
neutralization of intracellular pathways. Both means of inhibition have proven benefits in the …